Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy
- 1 April 1998
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 31 (1-2) , 89-104
- https://doi.org/10.1016/s0169-409x(97)00095-1
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Prodrugs and targeted drug deliveryAdvanced Drug Delivery Reviews, 1996
- Immunochemotherapy of human colon carcinoma xenografts in nude mice using combinations of idarubicin‐monoclonal antibody conjugatesImmunology & Cell Biology, 1993
- Inhibition of human renal cancer by monoclonal-anti-body-linked methotrexate in an ascites tumor modelCancer Immunology, Immunotherapy, 1991
- Antibody conjugates with morpholinodoxorubicin and acid cleavable linkersBioconjugate Chemistry, 1990
- The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancerBioconjugate Chemistry, 1990
- Preparation and in vitro cytotoxicity of a methotrexate‐anti‐MM46 monoclonal antibody conjugate via an oligopeptide spacerInternational Journal of Cancer, 1989
- New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activityJournal of Medicinal Chemistry, 1989
- Monoclonal antibody drug conjugates for site-directed cancer chemotherapy: preclinical pharmacology and toxicology studiesCancer Treatment Reviews, 1987
- Cis-aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkage releasing drug from a lysosomotropic conjugateBiochemical and Biophysical Research Communications, 1981
- Melanotropin–daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cellsNature, 1977